Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators

Hepatocellular Carcinoma Clinical Trial

— COLLAT-COVID  

Official title:

Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators to Follow-up the Activities of Different Cancer Pathologies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05932719
• Other study ID #: 69HCL20_0697
• Status: Recruiting
• Start date: December 1, 2022
• Est. completion date: December 1, 2024

Study information

• Verified date: July 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The COVID-19 pandemic has deeply and globally impacted usual procedures and patients management in cancer centers. The aim of this study is to set-up and collect indicators to follow-up the activities of different cancer pathologies before and during the pandemic. Patients loss' of chance will be analysed in term of diagnosis and access to care (surgery, antineoplastic treatments).

Data collection will focus on the analysis of 2 specific pathologies for French patients in the "Auvergne-Rhône Alpes" Area: peritoneal carcinosis and hepatocellular carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 4000
• Est. completion date: December 1, 2024
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.

Exclusion Criteria:

• Patients who did not allow the reuse of their medical data for research

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• COVID-19
• Hepatocellular Carcinoma
• Peritoneal Carcinoma

Intervention

Other:
• COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.
The following items will be collected Diagnostic date Diagnostic stage Date of surgery Date of surgery appointment First antineoplastic treatment date Last antineoplastic treatment date Number of treatment cycles recommanded by MDTM

Locations

Country	Name	City	State
France	Hopital Lyon sud, Hospices civils de Lyon	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019)	The difference between a set of different activity indicators will be compared between 2020 and the average activities of previous periods (2017-2019)	24 months